Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04756037 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
A Phase 3 study of Contraception, sponsored by Sumitomo Pharma Switzerland.
- Active
- Registry status
- Phase 3
- Development phase
- 1,020
- Enrollment target
- 20
- Study locations
NCT04756037 is a Phase 3 study of Contraception that is active but no longer recruiting, run by Sumitomo Pharma Switzerland. The registered enrollment target is 1,020 participants, above the 440-participant average among 72 other Contraception trials with a reported enrollment target (132% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT04756037, a Phase 3 study of Contraception, is active but no longer recruiting, sponsored by Sumitomo Pharma Switzerland.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,020 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the contraceptive efficacy of relugolix combination therapy.
Conditions Studied
Interventions
- DRUG Relugolix Combination Therapy
Study Locations (20)
California
- Burbank - Burbank
- Canoga Park - Canoga Park
- Encinitas - Encinitas
- Gardena - Gardena
- Lancaster - Lancaster
- Long Beach - Long Beach
- Long Beach - Long Beach
- Palo Alto - Palo Alto
- Sacramento - Sacramento
- San Diego - San Diego
- San Fernando - San Fernando
- Valley Village - Valley Village
- West Covina - West Covina
Arizona
- Chandler - Chandler
- Mesa - Mesa
- Peoria - Peoria
- Phoenix - Phoenix
Colorado
- Aurora - Aurora
- Greenwood Village - Greenwood Village
Alabama
- Mobile - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,020 participants |
| Start Date | 2021-03-18 |
| Est. Completion | 2026-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04756037
The ClinicalTrials.gov registry entry for NCT04756037 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,020 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 440-participant average among 72 other Contraception trials with a reported enrollment target (132% higher). The listed sponsor is Sumitomo Pharma Switzerland, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which Relugolix Combination Therapy is the first listed.
NCT04756037 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT04756037 about?
NCT04756037 is a clinical study titled "Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy". The purpose of this study is to assess the contraceptive efficacy of relugolix combination therapy.
What is the current status of trial NCT04756037?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,020 participants. The study started on 2021-03-18. Estimated completion is 2026-02.
What conditions does trial NCT04756037 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT04756037?
The interventions under investigation include: Relugolix Combination Therapy (DRUG).
Who is sponsoring clinical trial NCT04756037?
This trial is sponsored by Sumitomo Pharma Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04756037 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.
COMPLETED · Phase 3
-
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles
COMPLETED · Phase 3
-
Study of Safety and Efficacy of an Oral Contraceptive
COMPLETED · Phase 3
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement
RECRUITING · Phase 4
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.